Duarte, CA Clinical Trials Report — May 2026

For Duarte residents considering participation in clinical research, May 2026 brings both urgent opportunities and significant new avenues for contributing to medical science. Across the city, a number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals.

A total of 37 clinical trials are slated to conclude within the next 90 days in Duarte. This urgency is particularly relevant for healthy volunteers, as 6 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

New Opportunities for Healthy Volunteers

Beyond the closing trials, May also introduces fresh opportunities for healthy individuals to get involved. Of the 17 new trials that opened this month, 2 are specifically looking for healthy volunteers. This adds to a total of 32 trials currently recruiting healthy participants in Duarte, providing numerous avenues for those interested in supporting medical research without having a specific condition.

Significant New Research Initiatives

This month, Duarte saw the opening of 17 new clinical trials, a notable increase from the 7 trials that launched in March 2026. This brings the total number of actively recruiting clinical trials in Duarte, CA, to 541 across 74 research facilities, underscoring the city's robust research landscape, particularly in specialized areas.

May brings several high-profile new trials to Duarte, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Immuneering Corporation is initiating a notable Phase 3 study, NCT07562152, "Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma." This trial aims for 510 participants to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with standard of care GnP alone.
• City of Hope Medical Center is sponsoring NCT07595874, "Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3." This Phase 2 trial tests how well giving botensilimab and balstilimab prior to surgery works for the treatment of advanced colorectal cancer that can be removed by surgery, aiming for 100 participants.
• Also from City of Hope Medical Center, NCT07582159 is a Phase 2 trial, "Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma." This study, with 35 participants, tests the safety, side effects, and effectiveness of this combination therapy for CLL/SLL.
• Another Phase 2 trial from City of Hope Medical Center, NCT07582172, focuses on "Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome." This study involves 35 participants.
• City of Hope Medical Center is also leading two studies focused on molecular profiling and prediction: NCT07587268, "Molecular Profiling for Risk Stratification in Appendiceal Cancer" (400 participants), and NCT07587229, "Alternative Splicing Based Prediction of Chemotherapy Response in Gastric Cancer" (329 participants). These studies aim to improve understanding and treatment prediction for these cancers.

New trials this month are exploring a range of conditions, with the most frequent being hematopoietic and lymphatic system neoplasm (2 trials), refractory acute myeloid leukemia (2 trials), recurrent acute myeloid leukemia (2 trials), and malignant solid neoplasm (2 trials). Other conditions include anatomic stage iii breast cancer, advanced colorectal adenocarcinoma, biliary tract neoplasms, and chronic lymphocytic leukemia. Procedure-based trials account for the largest share of new studies, with 12 new procedure trials, followed by 9 drug trials.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various cancers and blood disorders are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Myelodysplastic syndromes (4 trials)
• Acute myeloid leukemia (3 trials)
• Colorectal cancer (3 trials)
• Lung non-small cell carcinoma (2 trials)
• Malignant solid neoplasm (2 trials)
• CRC (colorectal cancer) (2 trials)
• Cholangiocarcinoma (2 trials)
• Gastric cancer (2 trials)
• Colorectal cancer stage ii (2 trials)
• Colorectal cancer stage iii (2 trials)

Duarte's Leading Research Facilities

Duarte is home to a prominent research institution, which consistently runs a high volume of clinical trials. This facility is a key destination for individuals seeking to participate in medical research:

• City of Hope Medical Center (154 trials)
• City of Hope (130 trials)
• City of Hope Comprehensive Cancer Center (95 trials)
• City of Hope National Medical Center (43 trials)
• Research Site (25 trials)
• City of Hope (City of Hope National Medical Center, City of Hope Medical Center) (11 trials)
• City of Hope Cancer Center (7 trials)
• City of Hope - Duarte Cancer Center (5 trials)
• City of Hope - Duarte (4 trials)
• City Of Hope (4 trials)
• City of Hope Duarte (2 trials)
• City of Hope ( Site 0014) (2 trials)

These institutions, primarily under the City of Hope umbrella, offer a broad spectrum of research, with a strong focus on oncology and related medical fields.

Broadening Your Search: Nearby Options

While Duarte offers a significant array of clinical trial opportunities, individuals may also find options in nearby communities within California. Cities with active trials include Los Angeles (31 trials), San Francisco (27 trials), Palo Alto (12 trials), Irvine (11 trials), San Diego (11 trials), La Jolla (8 trials), Stanford (7 trials), and Sacramento (6 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 17 new trials launched this month, all 17 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. There are no new trials specifically for children, or designated as female-only or male-only this month. Academic institutions, particularly City of Hope Medical Center (16 trials), continue to play a vital role in Duarte's research ecosystem, with industry sponsors like Immuneering Corporation (1 trial) also driving significant research efforts.

As we move further into spring, Duarte's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.